NERV
Minerva Neurosciences, Inc.
Key Financials
Operating Income
$-15102970
↑ 30.9%
Revenue
$0
NaN%
Net Income
$-293423177
↓ 20492.7%
EPS (Diluted)
$-34.67
↓ 18347.4%
Total Assets
$98.0M
↑ 163.8%
Shareholders' Equity
$-140748082.00
↓ 447.8%
Cash & Equivalents
$82.3M
↑ 285.3%
Total Liabilities
$233.8M
↑ 272.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/13/2026 | View on SEC |
| 8-K | 8/12/2026 | View on SEC |
| 10-Q | 8/7/2026 | View on SEC |
| 8-K | 8/7/2026 | View on SEC |
| 4 | 8/3/2026 | View on SEC |
| SCHEDULE 13G/A | 7/8/2026 | View on SEC |
| 4 | 6/5/2026 | View on SEC |
| 4 | 6/5/2026 | View on SEC |
| 4 | 6/5/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | NERV |
| Company Name | Minerva Neurosciences, Inc. |
| CIK | 1598646 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | MA |
| Phone | 617-600-7373 |